Author: Zarate, C.A.J.; Quiroz, J.A.; Singh, J.B.; Denicoff, K.D.; De Jesus, G.; Luckenbaugh, D.A.; Charney, D.S.; Manji, H.K.
Description:
BACKGROUND: Preclinical and clinical evidence indicate that the glutamatergic system might play a role in the pathophysiology of mood disorders. This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in bipolar depression.
METHODS: This was an 8-week add-on study of riluzole in combination with lithium in acutely depressed bipolar patients aged 18 years and older. After open treatment with lithium for a minimum period of 4 weeks, subjects who continued to have a Montgomery-Asberg Depression Rating Scale (MADRS) score of >/=20 received riluzole (50-200 mg/day) for 8 weeks.
RESULTS: Fourteen bipolar depressed patients entered the study. The linear mixed models for total MADRS score showed a significant treatment effect. No switch into hypomania or mania was observed. Overall, riluzole was well tolerated.
CONCLUSIONS: Although preliminary, these results suggest that riluzole might indeed have antidepressant efficacy in subjects with bipolar depression.
Subject headings: Adolescent; Adult; Aged; Bipolar Disorder/drug therapy; Drug Therapy, Combination; Excitatory Amino Acid Antagonists/therapeutic use; Female; Humans; Lithium/therapeutic use; Male; Middle Aged; Personality Inventory; Psychiatric Status Rating Scales; Riluzole/therapeutic use; Time Factors; Treatment Outcome
Publication year: 2005
Journal or book title: Biological Psychiatry
Volume: 57
Issue: 4
Pages: 430-432
Find the full text :Â https://www.sciencedirect.com/science/article/pii/S0006322304012259
Find more like this one (cited by): https://scholar.google.com/scholar?cites=15637955768551055604&as_sdt=1000005&sciodt=0,16&hl=en
Type: Journal Article
Serial number: 1019